The Impact of Hepatitis B Vaccination Status on the Risk of Diabetes, Implicating Diabetes Risk Reduction by Successful Vaccination

被引:18
作者
Huang, Jean [1 ,2 ]
Ou, Horng-Yih [3 ]
Lin, James [4 ]
Karnchanasorn, Rudruidee [5 ]
Feng, Wei [1 ,2 ]
Samoa, Raynald [1 ,2 ]
Chuang, Lee-Ming [6 ,7 ]
Chiu, Ken C. [1 ,2 ]
机构
[1] City Hope Natl Med Ctr, Dept Clin Diabet Endocrinol & Metab, 1500 E Duarte Rd, Duarte, CA 91010 USA
[2] Harbor UCLA Med Ctr, Dept Internal Med, Div Endocrinol Metab & Nutr, Torrance, CA 90509 USA
[3] Natl Cheng Kung Univ, Med Coll & Hosp, Dept Internal Med, Div Endocrinol & Metab, Tainan 70101, Taiwan
[4] City Hope Natl Med Ctr, Dept Gastroenterol, Duarte, CA 91010 USA
[5] Univ Kansas, Med Ctr, Div Endocrinol, Dept Med, Kansas City, KS 66103 USA
[6] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan
[7] Natl Taiwan Univ, Sch Publ Hlth, Grad Inst Prevent Med, Taipei 10764, Taiwan
关键词
LIFE-STYLE INTERVENTION; IMPAIRED GLUCOSE-TOLERANCE; VIRUS-INFECTION; C VIRUS; LIVER-DISEASE; UNITED-STATES; FOLLOW-UP; PREVENTION; TRIAL; PREVALENCE;
D O I
10.1371/journal.pone.0139730
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background The liver plays a key role in fuel metabolism. It is well established that liver disease is associated with an increased risk for diabetes mellitus. Hepatitis C virus infection has been known to increase the risk of diabetes. However, much less is known about the role of hepatitis B virus (HBV) infection in diabetes. We examined the association of diabetes based on the vaccination status for HBV. Methods In this cross-sectional study, we included adult subjects (>= 20 y/o) with HBV serology available from the National Health and Nutrition Examination Survey 2005-2010. Diabetes was defined as established diabetes or fasting plasma glucose concentration >= 7.0 mmol/L, 2-hour plasma glucose concentration >= 11.1 mmol/L, or HbA1c >= 47.5 mmol/mol (6.5%). Vaccination was based on the reported history and immunization was determined by HBV serology. The odds ratio (OR) with 95% confidence intervals (95% CI) were calculated with consideration of the following covariates: age, gender, BMI, ethnic/racial group, current smoker, current alcohol consumption, family history of diabetes, poverty index, and education. Results This study included 15,316 subjects. Among them, 2,320 subjects was immunized based the HBV serology. Among 4,063 subjects who received HBV vaccination, successful vaccination was only noted in 39% of subjects. The HBV vaccination was not associated with diabetes (OR: 1.08, 95% CI: 0.96-1.23). Serology evidence of HBV immunization was associated with a reduced OR of diabetes (0.75, 95% CI: 0.62-0.90). Successful HBV vaccination was also associated with a reduced OR of diabetes (0.67, 95% CI: 0.52-0.84). Conclusions Although our study shows the association of HBV vaccination with the reduced odds of diabetes by 33%, a prospective study is warranted to confirm and examine the impact of HBV vaccination in prevention of diabetes.
引用
收藏
页数:14
相关论文
共 32 条
[1]  
Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc11-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S067, 10.2337/dc12-s011, 10.2337/dc10-S011, 10.2337/dc10-S062, 10.2337/dc13-S011, 10.2337/dc12-s064]
[2]  
[Anonymous], NATIONAL DIABETES ST
[3]   Endocrine manifestations of hepatitis C virus infection [J].
Antonelli, Alessandro ;
Ferri, Clodoveo ;
Ferrari, Silvia Martina ;
Colaci, Michele ;
Sansonno, Domenico ;
Fallahi, Poupak .
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2009, 5 (01) :26-34
[4]   HUMORAL IMMUNE-RESPONSE TO A YEAST-DERIVED HEPATITIS-B VACCINE IN PATIENTS WITH TYPE-1 DIABETES-MELLITUS [J].
BOUTER, KP ;
DIEPERSLOOT, RJA ;
WISMANS, PJ ;
MEYLING, FHIG ;
HOEKSTRA, JBL ;
HEIJTINK, RA ;
VANHATTUM, J .
DIABETIC MEDICINE, 1992, 9 (01) :66-69
[5]   Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children [J].
Chang, MH ;
Chen, CJ ;
Lai, MS ;
Hsu, HM ;
Wu, TC ;
Kong, MS ;
Liang, DC ;
Shau, WY ;
Chen, DS .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (26) :1855-1859
[6]   Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
DIABETOLOGIA, 2004, 47 (06) :969-975
[7]   Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance [J].
DeFronzo, Ralph A. ;
Tripathy, Devjit ;
Schwenke, Dawn C. ;
Banerji, MaryAnn ;
Bray, George A. ;
Buchanan, Thomas A. ;
Clement, Stephen C. ;
Henry, Robert R. ;
Hodis, Howard N. ;
Kitabchi, Abbas E. ;
Mack, Wendy J. ;
Mudaliar, Sunder ;
Ratner, Robert E. ;
Williams, Ken ;
Stentz, Frankie B. ;
Musi, Nicolas ;
Reaven, Peter D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (12) :1104-1115
[8]   From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus [J].
DeFronzo, Ralph A. .
DIABETES, 2009, 58 (04) :773-795
[9]   Hepatitis B vaccination in diabetic patients - Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen [J].
Douvin, C ;
Simon, D ;
Charles, MA ;
Deforges, L ;
Bierling, P ;
Lehner, V ;
Budkowska, A ;
Dhumeaux, D .
DIABETES CARE, 1997, 20 (02) :148-151
[10]   Insulin resistance and hepatitis C: an evolving story [J].
Eslam, Mohammed ;
Khattab, Mahmoud AboElneen ;
Harrison, Stephen A. .
GUT, 2011, 60 (08) :1139-1151